DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Galbán, Stefanie ^a   Lemasson, Benjamin ^b   Williams, Terence M ^a   Li, Fei ^b   Heist, Kevin A ^b   Johnson, Timothy D ^a   Leopold, Judith S ^a   Chenevert, Thomas L ^a   Lawrence, Theodore S ^b   Rehemtulla, Alnawaz ^a,b   Mikkelsen, Tom ^c   Holland, Eric C ^d   Galbán, Craig J ^b   Ross, Brian D ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GEMCITABINE; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DISEASE MODEL; GLIOBLASTOMA; IONIZING RADIATION; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; PHYSICAL TOLERANCE; RADIOSENSITIZATION; TRANSGENIC MOUSE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELLULARITY; TUMOR DIFFUSION; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BRAIN TUMOR; CELL LINE; CHEMORADIOTHERAPY; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HUMAN; KAPLAN MEIER METHOD; PATHOLOGY; RADIATION EXPOSURE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CELL LINE; CHEMORADIOTHERAPY; DACARBAZINE; DEOXYCYTIDINE; DIFFUSION MAGNETIC RESONANCE IMAGING; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84859966208     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035857     Document Type: Article

References (47)

1. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, et al. (2006) Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 11: 165-180.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
3. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
4. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, et al. (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol 12: 49-57.
5. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, et al. (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10: 1871-1874.
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
7. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, et al. (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6: 39-51.
8. Pauwels B, Korst AE, Lardon F, Vermorken JB, (2005) Combined modality therapy of gemcitabine and radiation. Oncologist 10: 34-51.
9. Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, et al. (2010) Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemother Pharmacol 65: 391-397.
10. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG, (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280.
11. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al. (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972.
12. Day SE, Kettunen MI, Cherukuri MK, Mitchell JB, Lizak MJ, et al. (2011) Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic resonance spectroscopic imaging. Magn Reson Med 65: 557-563.
13. la Fougere C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC, (2011) Molecular imaging of gliomas with PET: Opportunities and limitations. Neuro Oncol 13: 806-819.
14. Waldman AD, Jackson A, Price SJ, Clark CA, Booth TC, et al. (2009) Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol 6: 445-454.
15. Galban CJ, Bhojani MS, Lee KC, Meyer CR, Van Dort ME, et al. (2010) Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res 16: 1542-1552.
16. Chenevert TL, Ross BD, (2009) Diffusion imaging for therapy response assessment of brain tumor. Neuroimaging Clin N Am 19: 559-571.
17. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, et al. (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92: 2029-2036.
18. Le Bihan D, (1995) Molecular diffusion, tissue microdynamics and microstructure. NMR Biomed 8: 375-386.
19. Ross BD, Chenevert TL, Kim B, Ben-Yoseph O, (1994) Magnetic resonance imaging and spectroscopy: application to experimental neuro-oncology. Q Magn Reson Biol Med 1: 89-106.
20. Chenevert TL, McKeever PE, Ross BD, (1997) Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3: 1457-1466.
21. Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, et al. (2002) Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360: 307-308.
22. Dudeck O, Zeile M, Pink D, Pech M, Tunn PU, et al. (2008) Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 27: 1109-1113.
23. Cui Y, Zhang XP, Sun YS, Tang L, Shen L, (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248: 894-900.
24. Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, et al. (2007) Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 18: 957-963.
25. Momota H, Holland EC, (2009) Mouse models of CNS embryonal tumors. Brain Tumor Pathol 26: 43-50.
26. Jones TS, Holland EC, (2011) Molecular pathogenesis of malignant glial tumors. Toxicol Pathol 39: 158-166.
27. Fisher GH, Orsulic S, Holland E, Hively WP, Li Y, et al. (1999) Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 18: 5253-5260.
28. Orsulic S, (2002) An RCAS-TVA-based approach to designer mouse models. Mamm Genome 13: 543-547.
29. Tchougounova E, Kastemar M, Brasater D, Holland EC, Westermark B, et al. (2007) Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene 26: 6289-6296.
30. Pitter KL, Galban CJ, Galban S, Tehrani OS, Li F, et al. (2011) Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One 6: e14545.
31. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, et al. (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15: 1913-1925.
32. Dai C, Lyustikman Y, Shih A, Hu X, Fuller GN, et al. (2005) The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia 7: 397-406.
33. Koutcher JA, Hu X, Xu S, Gade TP, Leeds N, et al. (2002) MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia 4: 480-485.
34. McConville P, Hambardzumyan D, Moody JB, Leopold WR, Kreger AR, et al. (2007) Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res 13: 2897-2904.
35. Hamstra DA, Galban CJ, Meyer CR, Johnson TD, Sundgren PC, et al. (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26: 3387-3394.
36. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, et al. (2010) Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31: 538-548.
37. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, et al. (2005) Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 102: 16759-16764.
38. Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, et al. (2006) The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8: 259-267.
39. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, et al. (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235.
40. Sigmond J, Honeywell RJ, Postma TJ, Dirven CM, de Lange SM, et al. (2009) Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol 20: 182-187.
41. Ostruszka LJ, Shewach DS, (2000) The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine. Cancer Res 60: 6080-6088.
42. Hu X, Holland EC, (2005) Applications of mouse glioma models in preclinical trials. Mutat Res 576: 54-65.
43. Gupta T, Sarin R, (2002) Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol 3: 557-564.
44. van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, et al. (2007) Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 69: 1246-1253.
45. Preusser M, Capper D, Hartmann C, (2011) IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol 30: 217-230.
46. Gertler SZ, MacDonald D, Goodyear M, Forsyth P, Stewart DJ, et al. (2000) NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann Oncol 11: 315-318.
47. Fabi A, Mirri A, Felici A, Vidiri A, Pace A, et al. (2008) Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. J Neurooncol 87: 79-84.